ArticleBritish journal of cancer2026
SLFN11 enhances cisplatin sensitivity in pediatric cancer via activation of stress-response and suppression of survival pathways.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaediatric cancers pose treatment challenges due to biological heterogeneity and variable chemotherapy responses. SLFN11, a DNA/RNA helicase-like protein known to sensitise adult tumours to DNA-damaging agents, remains underexplored in paediatric malignancies.
methodsWe examined SLFN11 in Wilms tumour, osteosarcoma, and medulloblastoma using bioinformatics, epigenetic profiling and functional assays. Public datasets (TARGET, ICGC) were analysed to assess SLFN11 expression in relation to survival. Paediatric cancer cell lines were evaluated for baseline expression and promoter methylation. CRISPR-dCas9-mediated activation was used to restore SLFN11, and chemosensitivity was tested with cisplatin and the PARP inhibitor talazoparib. Transcriptomic profiling under cisplatin exposure was performed to identify pathways regulated by SLFN11.
resultsSLFN11 showed tumour type-specific correlations with patient outcome, acting as a positive, negative, or neutral predictor depending on cancer context. Promoter methylation regulated SLFN11 expression in paediatric cancers similarly to adult tumours. SLFN11 activation sensitised all three functionally tested cell lines to cisplatin and talazoparib, with transcriptomics showing its role in DNA damage response and MAPK signalling to enhance chemotherapy cytotoxicity.
conclusionIn paediatric solid tumours, SLFN11 is a potential predictive biomarker of treatment response. Its ability to dictate the DNA damage landscape through epigenetic modulation highlights its significance as a target for overcoming chemoresistance and improving therapeutic efficacy in young patients. SLFN11 functions as a context-dependent biomarker of outcome and chemotherapy response in paediatric solid tumours. Its epigenetic regulation and modulation of DNA damage highlights SLFN11 as a therapeutic target to overcome chemoresistance.
Identifiers
42686854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.